Rolls-Royce has received awards valued at $16 million for its participation in the FAA’s Continuous Lower Energy, Emissions & Noise (Cleen) technologies program, the company announced today.
Under the terms of the contract, Rolls-Royce will perform engine test demonstrations specifically focused on reduced fuel burn technologies and evaluating alternative aviation fuels. Cleen program goals center on achieving a 33-percent reduction in fuel burn against a baseline of current performance technology and advancing sustainable alternative aviation fuels by 2015.
Rolls-Royce expects to perform the fuel-burn segment of the Cleen program in concert with undertakings already established under the Environmentally Friendly Engine program. The engine maker plans to evaluate alternative product designs to achieve gains in cycle efficiency and, hence, fuel burn cuts through reductions in turbine cooling airflow. It plans to design and manufacture the alternative parts at its plant in Indianapolis and conduct testing in Bristol, UK.
The company plans to conduct component, engine, rig and flight testing of alternative fuels using accepted ASTM International procedures on a Rolls-Royce AE3007 engine and a Cessna Citation X. Rolls-Royce has committed to carrying out testing at its Indianapolis facility and Cessna at its Wichita plant.
Meanwhile, a complementary alternative fuels program of laboratory-scale, rig and engine testing will take place in a controlled environment at Rolls-Royce facilities in Derby, UK.
The company aims to assess various characteristics of alternative fuels, including suitability, environmental sustainability and industrial and commercial viability. Rolls-Royce will further endeavor to build on the fundamental scientific understanding of the roles of alternative fuel properties and composition.
Rolls-Royce’s collaboration in the Cleen program complements its efforts to meet Acare (Advisory Council for Aeronautics Research in Europe) established targets of reducing CO2 and noise by half and NOx by 80 percent by 2020, compared with a baseline established in 2000.